Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease
This meta-analysis examines the use of cholinesterase inhibitors as treatment of psychotic symptoms in patients with Alzheimer disease, Parkinson disease, and dementia with Lewy bodies. (Source: JAMA Neurology)
Source: JAMA Neurology - June 26, 2023 Category: Neurology Source Type: research
Semont-Plus vs Epley Maneuver in Posterior Canal Benign Paroxysmal Positional Vertigo
This randomized clinical trial compares the efficacy of the Semont-plus maneuver and the Epley maneuver in patients with posterior canal benign paroxysmal positional vertigo. (Source: JAMA Neurology)
Source: JAMA Neurology - June 26, 2023 Category: Neurology Source Type: research
Visual Evoked Potentials in Acute Retinal Migraine
This case report describes monocular blurred vision and photopsia with headache. (Source: JAMA Neurology)
Source: JAMA Neurology - June 26, 2023 Category: Neurology Source Type: research
Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment
This randomized clinical trial investigates the safety and efficacy of ApTOLL as a neuroprotectant drug for patients with ischemic stroke when given in combination with endovascular treatment. (Source: JAMA Neurology)
Source: JAMA Neurology - June 20, 2023 Category: Neurology Source Type: research
Automated Interpretation of Clinical Electroencephalograms Using Artificial Intelligence
This diagnostic study investigates whether an artificial intelligence model can be trained to interpret clinical encephalograms similar to human experts. (Source: JAMA Neurology)
Source: JAMA Neurology - June 20, 2023 Category: Neurology Source Type: research
The New Era of Automated Electroencephalogram Interpretation
The electroencephalogram (EEG) is fundamental to the diagnosis and tailored management of epilepsy. Yet, its interpretation is far from being a plug-and-play process. Even among experts, variance in EEG interpretations and even epilepsy misdiagnosis are disappointingly common. Efforts to standardize criteria for EEG interpretation have helped, but they cannot eradicate the poor reliability of subjective interpretation and reliance on highly trained clinicians. (Source: JAMA Neurology)
Source: JAMA Neurology - June 20, 2023 Category: Neurology Source Type: research
Effectiveness of Lumbar Cerebrospinal Fluid Drain Among Patients With Aneurysmal Subarachnoid Hemorrhage
This pragmatic randomized clinical trial evaluates the effectiveness of early lumbar cerebrospinal fluid drainage added to standard of care in patients after aneurysmal subarachnoid hemorrhage. (Source: JAMA Neurology)
Source: JAMA Neurology - June 18, 2023 Category: Neurology Source Type: research
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
This cohort study investigates if rituximab is noninferior to ocrelizumab in the prevention of relapses and disability in patients with relapsing-remitting multiple sclerosis. (Source: JAMA Neurology)
Source: JAMA Neurology - June 12, 2023 Category: Neurology Source Type: research
Incident Epilepsy, Antiseizure Medications, and Development of Osteoporosis
This cohort study uses population-based data to quantify and model the independent hazards for osteoporosis associated with epilepsy and antiseizure medications. (Source: JAMA Neurology)
Source: JAMA Neurology - June 12, 2023 Category: Neurology Source Type: research
Abandoning the Proteinopathy Paradigm in Parkinson Disease —Not So Fast—Reply
In Reply Decades of research have sought not to question but to prove that proteins can turn into toxins, with most efforts focusing on only one side of the protein aggregation story —the pathology. It is worth remembering that pathology today was a normal protein yesterday. In response to our Viewpoint, Bronstein and colleagues stated that “…lower CSF amyloid β actually correlates with brain amyloid accumulation….” Because the correlation is inverse, our “oversimpl ification” was to propose that the decrease in CSF amyloid β may be more relevant than the increase in amyloid. (Source: JAMA Neurology)
Source: JAMA Neurology - June 12, 2023 Category: Neurology Source Type: research
Abandoning the Proteinopathy Paradigm in Parkinson Disease —Not So fast
To the Editor Espay and Okun recently proposed abandoning the proteinopathy paradigm in Parkinson disease (PD) in favor of a “proteinopenia” hypothesis. Loss of function as a possible mechanism for PD and other neurodegenerative diseases is not a new idea, and we agree that multiple potential mechanisms underlying neurodegeneration should be investigated. Although their theory is provocative, they vastly oversimplify complex topics and selectively cite/interpret studies with serious limitations to reach an ill-supported conclusion that would stifle our best developed line of therapeutic investigation. From the first se...
Source: JAMA Neurology - June 12, 2023 Category: Neurology Source Type: research
Cerebrospinal Fluid Venous Fistula Imaging with Ultrahigh-Resolution Cone-Beam Computed Tomography
This case report describes a cerebrospinal fluid venous fistula imaged with ultrahigh-resolution cone-beam computed tomography. (Source: JAMA Neurology)
Source: JAMA Neurology - June 12, 2023 Category: Neurology Source Type: research
New Approaches to Challenge Old Assumptions —B-Cell Depletion in Multiple Sclerosis
B-cell –depleting monoclonal antibodies (mAbs) have emerged as an arguably mechanistically dominant drug class in the multiple sclerosis (MS) disease-modifying therapy (DMT) armamentarium in recent years. As a group, they represent a high-efficacy treatment option for relapsing MS and offer some degree o f efficacy in progressive forms of MS. Ocrelizumab remains the only DMT approved for primary progressive MS. Current approved CD20–targeted mAbs for relapsing forms of MS include ocrelizumab, ofatumumab, and ublituximab. (Source: JAMA Neurology)
Source: JAMA Neurology - June 12, 2023 Category: Neurology Source Type: research
Error in Abstract
The Original Investigation titled “Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios,” published May 8, 2023, was corrected to change “higher eGFR” to “lower eGFR” in the second sentence of the Results section of the abstract. (Source: JAMA Neurology)
Source: JAMA Neurology - June 12, 2023 Category: Neurology Source Type: research
Error in Figure 3
In the Original Investigation titled “Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes,” which was published online April 27, 2020, the wrong image was published for Figure 3. The article was corrected online. (Source: JAMA Neurology)
Source: JAMA Neurology - June 12, 2023 Category: Neurology Source Type: research
